To access the session recording, navigate to the content tab and click the view video button. 

Session Schedule

Find a specific presentation in the session by navigating to the timestamp indicated below.

0:00:00
Introduction

0:01:09
Sleep and circadian rhythm disturbance in psychosis, does targeting sleep and circadian function improve outcomes?
Nicholas Meyer (United Kingdom)

0:25:36
A “wake up call” for nightmares in adults: Management and implications for mental health
Pierre Alexis Geoffroy (France)

0:53:20
Treating insomnia comorbid with mood and anxiety disorders: Data on CBT-I and pharmacological treatments
Laura Palagini (Italy)

1:14:35
Reducing suicidality through insomnia treatment is it possible?
Vaughn McCall (United States)

Summary
Sleep plays a critical regulatory role in mental health yet sleep disturbances may contribute to a state of allostatic overload, impairing brain neuroplasticity and stress-immune pathways, and ultimately exacerbating mental health disorders. This symposium aims to bridge the gap between current knowledge of sleep disturbances with emerging insights into the dysregulatory mechanisms underlying mental health conditions. We will also explore the latest advances in the treatment of sleep disorders and their impact on psychopathology.
The symposium will focus on the significant challenges posed by sleep disturbances in mood disorders, anxiety, psychotic disorders, and suicide risk. In this context, Dieter Riemann will introduce the rationale behind the symposium. Nick Meyer (London, UK) will present recent advances in understanding sleep and circadian rhythm disturbances in psychosis, addressing the question: Does targeting sleep and circadian function improve outcomes? Pierre Alexis Geoffroy (Paris, France) will explore the under-recognized and under-treated role of nightmares in clinical practice with his talk: A “Wake-up Call” for Nightmares in adults: Management and implications for Mental Health. Laura Palagini (Pisa, Italy) will present data on the treatment of insomnia and its preventive and therapeutic roles in mood and anxiety disorders, including new findings on dual orexin receptor antagonists (DORA), for treating insomnia in these disorders. Finally, Vaughn McCall (Augusta, USA) will discuss how regulating sleep can potentially reduce suicide risk in his talk: Reducing suicidality through insomnia treatment: is it possible?
This symposium promises to provide valuable insights into the interrelation of sleep and mental health, offering innovative approaches to managing these complex challenges in clinical practice.